Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bayer Aktienges ADR (OP: BAYRY ) 7.065 +0.075 (+1.07%) Streaming Delayed Price Updated: 12:22 PM EDT, Oct 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Bayer Aktienges ADR < Previous 1 2 3 4 5 6 Next > Bayer Seeks European Approval For Its Menopause Drug October 15, 2024 Bayer has submitted an MAA to the EMA for elinzanetant, targeting moderate to severe vasomotor symptoms linked to menopause. Phase 3 trials showed significant reductions in VMS and improved quality of... Via Benzinga Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide October 14, 2024 Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase III ARANOTE trial results. The treatment significantly lowers progression... Via Benzinga Week In Review: Zenas Raises $259 Million In IPO September 28, 2024 It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... Via Talk Markets Topics Initial Public Offering Exposures Securities Market Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea September 23, 2024 Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. Via Investor's Business Daily Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study September 16, 2024 Bayer's Phase 3 ARANOTE trial showed darolutamide plus androgen deprivation therapy (ADT) reduced the risk of radiological progression or death in metastatic hormone-sensitive prostate cancer patients... Via Benzinga Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer September 10, 2024 Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments. Via Benzinga Why Is BridgeBio Pharma Stock Trading Higher On Friday? August 30, 2024 BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... Via Benzinga BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024 August 06, 2024 BAYRY stock results show that Bayer met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer July 25, 2024 Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal 3 Longevity Stocks to Buy for Anti-Aging Breakthroughs July 08, 2024 Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. Via InvestorPlace 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M June 05, 2024 Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. Via Benzinga Exposures Glyphosate Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership June 01, 2024 Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... Via Talk Markets European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday? May 27, 2024 European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola. Via Benzinga After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February May 24, 2024 Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. Via Benzinga Topics Data Breach Exposures Information Security Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval May 17, 2024 Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. Via Benzinga Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... Via Benzinga BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024 May 14, 2024 BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch May 10, 2024 Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned May 02, 2024 Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... Via Benzinga Exposures Glyphosate Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades' April 10, 2024 On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is Via Benzinga Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists April 09, 2024 Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds April 05, 2024 Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from... Via Benzinga Topics Bonds Exposures Debt Markets Bayer-Backed Boundless Bio Falls After IPO March 31, 2024 Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company. Via Talk Markets Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant March 19, 2024 Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... Via Benzinga Exposures Product Safety German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits March 14, 2024 Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. Via Benzinga Topics Bankruptcy Lawsuit Exposures Financial Glyphosate Legal BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023 March 05, 2024 BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. Via InvestorPlace Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges March 05, 2024 Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. Via Benzinga Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits March 04, 2024 Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. Via InvestorPlace What's Going On With BridgeBio Pharma Stock On Monday? March 04, 2024 BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.